BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lefevre PLC, Vande Casteele N. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S725-36. [PMID: 32160283 DOI: 10.1093/ecco-jcc/jjaa014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Dal Buono A, Gabbiadini R, Solitano V, Vespa E, Parigi TL, Repici A, Spinelli A, Armuzzi A. Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy. Clin Exp Gastroenterol 2022;15:121-8. [PMID: 35909812 DOI: 10.2147/CEG.S350193] [Reference Citation Analysis]
2 Alexander M, Luo Y, Raimondi G, O'Shea JJ, Gadina M. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies. Pharmaceuticals (Basel) 2021;15:48. [PMID: 35056105 DOI: 10.3390/ph15010048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52. [PMID: 34450118 DOI: 10.1016/j.jaci.2021.08.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Gonciarz M, Pawlak-Buś K, Leszczyński P, Owczarek W. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy 2021;13:1135-50. [PMID: 34235974 DOI: 10.2217/imt-2021-0096] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Reddig A, Voss L, Guttek K, Roggenbuck D, Feist E, Reinhold D. Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage. J Clin Med 2021;10:1431. [PMID: 33916057 DOI: 10.3390/jcm10071431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Favoino E, Prete M, Catacchio G, Ruscitti P, Navarini L, Giacomelli R, Perosa F. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? Autoimmun Rev 2021;20:102750. [PMID: 33482338 DOI: 10.1016/j.autrev.2021.102750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
7 Nadpara N, Reichenbach ZW, Ehrlich AC, Friedenberg F. Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications. Dig Dis Sci 2020;65:2769-79. [PMID: 32661765 DOI: 10.1007/s10620-020-06471-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]